reason report
bottom line reiter op rate follow
result add convict org rev/ep growth acceler
thesi sustain hsd top-lin profil along
mid-teen ep growth next sever year cc revenue
cc top consensu led management increas full-year outlook
vs despit increment fx headwind
slightli lower int expense/tax rate allow management increas cc revenue
rang ep outlook midpoint continu believ plenti
levers/driv period drive hsd revenu growth
deliv mid-teen ep growth -- -a better profil mani
peer -- upsid potenti like manta japan neotract
addit restructur initi pt
assum price-to-earnings lower due increment fx ep
substanti ep upsid beat our/consensu
growth y/i came forecast
out-performance led urolift intervent urolog
cc vascular access cc surgic cc intervent
cc oem cc line anesthesia
cc cc under-perform slightli geograph
beat consensu asia cc emea cc
turn gm op margin reach highest
level compani histori beat us/consensu lower interest
expens tax rate vs think contribut half
ep beat adj ep beat consensu
medic suppli devic
ep
price-to-earnings lt ep growth
compani inform svb leerink llc research
revenu mm ep present note valuat base pf ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
cc revenue guidanc increas cc vs cc prior
report revenue guidanc decreas vs due
increas fx headwind vs prior impli top-
line result rang intervent urology/urolift
expect grow y/i vs impli revenue
growth y/i -- -like prove conserv see reason
ul growth deceler suggest guidanc management also
embed placehold headwind reflect closur
third-parti steril facil even disrupt though
compani track post comp adjust y/i cc revenue growth acceler
steril facil closur clearli unanticip
headwind manag management
alreadi dial cushion updat guid
epd/fda requir temporari closur third-parti sterigen
steril facil ga earli sept due concern ethylen
oxid emiss impact distribut medic devic
custom among other management believ updat full-yr
guidanc adequ handicap headwind
ep impact assum facil remain close throughout entir
management indic proactiv take step ensur
potenti risk mitig work valid steril
cycl sites/geographi anticip cycl valid
earli management sound extrem confid worst case dial
sterigen facil come back on-line qtr end
would upsid
lower end ep rang rais midpoint increas
impact management re-affirmed adj gm/op mgn guidanc rang
interest expens expect vs
prior adj tax rate expect vs low
end adj ep guidanc rais low end
vs prior
updat guidanc rang contempl increment fx impact
vs prior steril headwind
regard specif guidanc provid lrp
us y/i margin expans bigger vs ceo kelli
reiter continu believ today better posit
ever tenur drive top-lin growth
year ahead tailwind consid includ manta growth
accel driver compani nearli final price
strategi expect enter full launch urolift japan
management continu expect mid-to-l urolift japan approval/
launch bigger ramp acceler invest behind
dtc secur reimburs ramp meaning
meanwhil urolift begin roll-out full convers
us physician regard margin management expect annual
y/i margin improv progress increas throughout lrp
 given anticip time complet convers
time benefit form restructur project nonetheless
still expect bigger y/i improv vs part
model gm/op margin expans vs
gm/op margin expans vs
confid abl grow least cc top line
low-to-mid-teen bottom line upsid potenti like
model updat revenue vs prior reflect
reduc cc vs cc dial
fx headwind assumpt ep line
year price history/av daili volume mil
midpoint guidanc vs prior ep
reduc vs prior higher assum fx headwind
outperform rate pt light neotract acquisit see
clearer pathway toward hsd org sale growth rang
vascular solut vsi close feb neotract close deal organ
mix strong record execut come integr includ
under-promis over-deliv initi synergy/sal target less near-
term cost synergi potenti associ neotract top-lin accret potenti
excit us deal believ potenti transform hsd revenu
grower out-year also think could addit sales/ep momentum
out-year factor model consid increas contribut neotract
ou market bulk exist urolog footprint current sit urolift today
minim presenc eventu revenue contribut ezplaz frozen plasma
project possibl commerci time-frame increas revenue contribut
manta acquir essenti medic acquisit pma approv
potenti futur tuck-in addit restructur opportun addit
program alreadi underway project earn power ep compound-annual-growth-rate
op margin expans potenti given confid top-lin
acceler territori mid-teen ep growth profil -- -both
upper-end peersw think sustain current premium
group assum multipl ep suggest pt
trade ep premium versu peer
group hospit suppli compani compani relev
alc
trade ep given confid top-lin acceler
hsd territori margin expans driven acceler mid-to-high teen profit growth
profil -- -both upper-end peersw think fact widen
premium group appli multipl premium group
ep suggest pt wed note compani med-tech msd-
valuat could risk new product launch organiz improv effort
planned/prior integr synergi cost-cut effort prove challeng take longer
expect implement neotract acquisit integr time fashion
reason uptak compani urolift platform materi quickli
project could put pro forma sales/ep forecast risk well tough competit
larger hospit suppli compani could hinder abil make inroad new
product launch hospitalsin effort rein cost preserv profit given numer
global macroeconom challeng uncertainti relat political/healthcar reform tighten
belt grow less will negoti price hospit suppli product could make
harder drive higher product compani typic sold
discount market rate attempt bring market rate newli launch
achiev sustain price increas key driver long-term gross/oper margin
improv instrument order achiev long-term sales/profit goal
discret item neg impact organ cc revenue growth compani base busi
prove transient take longer resolv expect would like damag
management credibl decreas investor confid org revenue growth acceler thesi
key part invest thesi
dollar million except ep
svb leerink llc estim factset compani inform
dollar million except ep
svb leerink llc estim compani inform
restat report statement effect januari includ revenu geographi revenu product comparison prior
dollar million except ep
headwind fx
headwind fx greatest
headwind fx greatest
headwind fx greatest
impact
impact
impact
incl invest urolift
incl invest urolift
japan commerci
japan commerci
infrastructur manta well
addt urolift sales/dtc
infrastructur manta well
addt urolift sales/dtc
closer low-end
closer low end
compani report svb leerink llc estim
dollar million except per share data
good sold
dilut averag share million
sg adjust sale
sg adjust ex-amort sale
 total sale
oper expens adjust sale
oper expens adjust ex-amort sale
day adj sale organ growth rate ex- acq
compani report svb leerink llc estim
teleflex incorpor restat segment revenu
dollar million except per share data
sale mix
compani report svb leerink llc estim
restat report statement effect januari includ revenu geographi revenu product comparison prior estim
